Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World of Culture Times.
Press releases published on May 13, 2025
Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
GlobeNewswire
·
May 13, 2025
MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a …
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
Knight présentera à la conférence sur la santé internationale de 2025 de RBC Marchés des Capitaux à New York
GlobeNewswire
·
May 13, 2025
MONTRÉAL, 13 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, participera à une …
Command Alkon’s Batch AI Honored as a 2025 Concrete Contractor Top Products Award Winner
GlobeNewswire
·
May 13, 2025
BIRMINGHAM, Ala., May 13, 2025 (GLOBE NEWSWIRE) -- Concrete Contractor, the nationally recognized magazine serving concrete construction professionals, names Command Alkon’s Batch AI a 2025 Concrete Contractor Top Products award winner. The 2025 Concrete …
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
GlobeNewswire
·
May 13, 2025
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in …
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
GlobeNewswire
·
May 13, 2025
LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical impact of early-onset MLD Six accepted abstracts at ASGCT …
Digital Science to support U.S. government libraries through new FEDLINK partnership
GlobeNewswire
·
May 13, 2025
LONDON and CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Digital Science, a technology company serving stakeholders across the research ecosystem, will offer U.S. government libraries access to some of its most powerful research data and analytics …
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 13, 2025
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
May 13, 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswire
·
May 13, 2025
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate …
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 13, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
GlobeNewswire
·
May 13, 2025
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden …
Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT
GlobeNewswire
·
May 13, 2025
- Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity …
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
GlobeNewswire
·
May 13, 2025
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which …
Endeavour Silver Announces Q1 2025 Financial Results; Earnings Call at 10AM PDT (1PM EDT) Today
GlobeNewswire
·
May 13, 2025
VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three months ended March 31, 2025. All dollar amounts are in US …
Kingsoft Cloud to Report First Quarter 2025 Financial Results on May 28, 2025
GlobeNewswire
·
May 13, 2025
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX: 3896) (“Kingsoft Cloud” or the “Company”), a leading cloud service provider in China, today announced that it will release its unaudited financial results for …
Best No-Drill Blinds (2025): SelectBlinds Awarded Top Tool-Free Shades by Expert Consumers
GlobeNewswire
·
May 13, 2025
Boston, May 13, 2025 (GLOBE NEWSWIRE) -- SelectBlinds has been recognized as a top provider in the growing no-drill blinds category by Expert Consumers. With increased demand for quick-installation window solutions that do not require hardware or damage to …
Zhihu Inc. to Report First Quarter 2025 Financial Results on May 27, 2025
GlobeNewswire
·
May 13, 2025
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter ended March 31, 2025 …